Posted inCardiology Diabetes & Endocrinology news

SGLT2 Inhibitors Offer Potent Protection Against Contrast-Induced Kidney Injury During Coronary Intervention

No Comments
SGLT2 Inhibitors Offer Potent Protection Against Contrast-Induced Kidney Injury During Coronary Intervention

Highlight

Evidence of Reno-Protection

According to data from the BMC2 registry, patients with diabetes who were receiving SGLT2 inhibitors (SGLT2i) prior to percutaneous coronary intervention (PCI) experienced a 28% reduction in the odds of developing contrast-associated acute kidney injury (CA-AKI) compared to non-users.

Consistent Clinical Benefit

The protective signal remained robust even after rigorous propensity-score matching and risk adjustment, with the benefits extending to various high-risk patient subgroups, suggesting a broad clinical utility for these agents in the catheterization lab setting.

Addressing a Critical Gap

While the long-term renal benefits of SGLT2i are well-established for chronic kidney disease and heart failure, this study provides pivotal real-world evidence regarding their efficacy in mitigating the acute, toxic effects of iodinated contrast media during invasive cardiac procedures.

Background: The Challenge of CA-AKI in Interventional Cardiology

Contrast-associated acute kidney injury (CA-AKI) remains one of the most frequent and clinically significant complications following percutaneous coronary intervention (PCI). For patients with diabetes mellitus, the risk is particularly pronounced due to underlying microvascular dysfunction, oxidative stress, and a higher prevalence of pre-existing chronic kidney disease (CKD). CA-AKI is not merely a transient elevation in serum creatinine; it is independently associated with prolonged hospitalization, increased healthcare costs, and a heightened risk of long-term progression to end-stage renal disease and major adverse cardiovascular events (MACE).

Historically, the management of CA-AKI risk has been limited to periprocedural hydration and the minimization of contrast volume. Pharmacological interventions, including N-acetylcysteine and various vasodilators, have largely failed to show consistent benefits in large-scale clinical trials. Consequently, there is an urgent need for novel therapeutic strategies that can protect the renal parenchyma from the hemodynamic and cytotoxic insults inherent in contrast administration.

SGLT2 inhibitors have revolutionized the management of type 2 diabetes, heart failure, and CKD. By inhibiting the sodium-glucose cotransporter 2 in the proximal tubule, these agents promote glycosuria and natriuresis. More importantly, they restore tubuloglomerular feedback, leading to afferent arteriolar vasoconstriction and a reduction in intraglomerular pressure. While this mechanism leads to an initial, reversible dip in the glomerular filtration rate (GFR), it ultimately preserves renal function over time. However, the role of SGLT2i in the acute setting of contrast exposure has been a subject of debate, with some clinicians concerned that the initial GFR dip might exacerbate acute injury. The BMC2 registry study provides essential clarity on this clinical dilemma.

Study Design and Methodology

The researchers utilized data from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) PCI registry, a comprehensive, multi-center clinical database that captures all PCI cases at nonfederal hospitals across the state of Michigan. This retrospective analysis focused on a contemporary cohort of patients with diabetes who underwent PCI between January 2022 and September 2023.

Inclusion and Exclusion Criteria

The study population included all diabetic patients enrolled in the registry during the study period. To ensure data integrity and clinical relevance, the researchers excluded patients currently on dialysis and those for whom post-procedural serum creatinine measurements were unavailable. The final analysis included 13,804 patients, representing a substantial real-world sample.

Study Endpoints

The primary endpoint was the incidence of CA-AKI, defined as an absolute increase in serum creatinine of ≥0.5 mg/dL from the baseline value following the PCI procedure. This definition is a standard metric used in interventional cardiology to identify clinically significant renal impairment.

Statistical Approach

To account for the inherent biases of a retrospective registry, the investigators employed a risk-adjusted, propensity-matched analysis. This methodology allowed for a balanced comparison between SGLT2i users and non-users by matching individuals based on a wide array of baseline characteristics, including age, baseline renal function, left ventricular ejection fraction, and procedural complexity. This rigorous approach enhances the reliability of the findings by minimizing the impact of confounding variables.

Key Findings: Significant Risk Reduction

The results of the BMC2 registry analysis underscore a clear and significant reno-protective effect associated with preprocedural SGLT2i therapy.

Primary Outcomes

Among the total cohort of 13,804 diabetic patients, the raw incidence of CA-AKI was 3.8% (82/2,186) in the SGLT2i user group compared to 5.2% (602/11,618) in the non-user group. This translated to an unadjusted odds ratio (OR) of 0.71 (P=0.004). Following propensity-score matching and risk adjustment, the difference remained statistically significant. In the matched analysis, the incidence of CA-AKI was 3.69% for SGLT2i users versus 4.68% for non-users, resulting in an adjusted odds ratio of 0.72 (P=0.027).

Subgroup Consistency

One of the most compelling aspects of the study was the consistency of the findings across various patient subgroups. The protective effect of SGLT2i was preserved regardless of baseline kidney function (eGFR), age, or the presence of heart failure. Even in patients traditionally considered at higher risk for CA-AKI, the use of SGLT2i was associated with a lower risk of post-procedural renal impairment.

Expert Commentary: Mechanistic Insights and Clinical Implications

Biological Plausibility

The observed reno-protection in this study is biologically plausible when considering the unique hemodynamic and metabolic effects of SGLT2 inhibitors. Contrast media causes CA-AKI through several pathways: direct toxicity to renal tubular cells, induction of oxidative stress, and profound vasoconstriction of the vasa recta, which leads to medullary hypoxia. The renal medulla is particularly susceptible to ischemic injury because it operates at a very low oxygen tension even under normal conditions.

SGLT2 inhibitors may mitigate these effects by reducing the metabolic demand of the proximal tubule. By blocking the active transport of sodium and glucose, these agents decrease the workload and oxygen consumption of the tubular cells. This metabolic sparing effect may render the kidney more resilient to the transient hypoxia induced by contrast media. Furthermore, the restoration of tubuloglomerular feedback may prevent the excessive hyperfiltration and subsequent tubular stress that can follow contrast-induced hemodynamic shifts.

Clinical Considerations and the SGLT2i Dip

A common concern in clinical practice is the temporary decrease in eGFR observed upon initiation of SGLT2i therapy. Some practitioners have questioned whether this dip might increase the risk of AKI during acute stressors like PCI. However, the BMC2 registry data suggest the opposite: the hemodynamic modifications induced by SGLT2i appear to be protective rather than harmful in the context of contrast exposure. This aligns with findings from other cardiovascular trials where SGLT2i demonstrated a reduction in AKI events across various clinical scenarios.

Managing the Risk of Euglycemic DKA

While the renal benefits are clear, clinicians must remain mindful of the risk of euglycemic diabetic ketoacidosis (DKA), particularly in the peri-operative or peri-procedural period when patients may experience dehydration or reduced oral intake. Current guidelines often suggest pausing SGLT2i for 3 to 4 days before major surgery. However, for a procedure like PCI, which is minimally invasive and often involves a rapid return to normal diet and activity, the risk-benefit ratio may favor maintaining SGLT2i therapy to harness its reno-protective effects. This study suggests that if a patient is already on these agents, they should likely be continued through the procedure, provided the patient is not at high risk for DKA.

Conclusion: A New Paradigm in Renal Protection

The findings from the BMC2 registry provide a significant contribution to our understanding of peri-procedural care in interventional cardiology. Among patients with diabetes undergoing PCI, the pre-procedural use of SGLT2 inhibitors is independently associated with a lower risk of contrast-associated acute kidney injury. This research challenges the traditional cautious approach of withholding these medications and instead highlights their potential as a proactive tool for renal preservation.

As SGLT2 inhibitors continue to solidify their place as a foundational therapy in cardiovascular and metabolic medicine, their role in acute procedural settings will likely expand. While randomized controlled trials are needed to definitively confirm these findings and establish specific timing protocols, the current evidence suggests that SGLT2i therapy offers a powerful shield for the kidneys during the high-stakes environment of the cardiac catheterization lab.

References

1. Hyder SN, Seth M, Hamilton DE, et al. Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry. Circ Cardiovasc Interv. 2026 Feb 5:e015645. doi: 10.1161/CIRCINTERVENTIONS.125.015645.
2. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.
3. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306.
4. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155.

Tags:
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

No Comments
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

Highlight

  • SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% (HR 0.62), with benefits consistent across all stages of kidney function.
  • Significant renoprotection was observed even in patients with Stage 4 CKD (eGFR <30 mL/min/1.73 m2) and those with minimal albuminuria (UACR ≤30 mg/g).
  • The therapy slowed the annual rate of eGFR decline and reduced the risk of kidney failure by 34%, independent of diabetes status.
  • Results support the routine use of SGLT2 inhibitors as a foundational therapy for kidney protection across a much broader patient population than previously established.

Background: The Evolution of Renoprotection

For decades, the management of chronic kidney disease (CKD) was largely limited to blood pressure control and the use of renin-angiotensin system (RAS) inhibitors. The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors has fundamentally shifted the treatment paradigm. Originally developed as glucose-lowering agents for type 2 diabetes, these drugs demonstrated unexpected and profound cardiorenal benefits in large-scale cardiovascular outcome trials. Subsequent dedicated kidney trials, such as CREDENCE, DAPA-CKD, and EMPA-KIDNEY, solidified their role in slowing the progression of kidney disease.

Despite this progress, clinical uncertainty remained regarding specific patient subgroups. Most earlier trials focused on patients with significant albuminuria or moderately reduced glomerular filtration rates (eGFR). Clinicians have questioned whether the renoprotective benefits extend to those with very low eGFR (Stage 4 CKD) or those without significant albuminuria, who have historically been considered at lower immediate risk for progression but still face long-term kidney failure risk. To address these gaps, the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C) conducted a comprehensive meta-analysis to provide definitive evidence across the full spectrum of kidney function.

Study Design and Methodology

The SMART-C meta-analysis pooled data from 10 randomized, double-blind, placebo-controlled trials. These trials evaluated SGLT2 inhibitors (including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) with label indications or significant data regarding CKD progression. The inclusion criteria required trials to have at least 500 participants per group and a minimum of six months of follow-up.

The study population comprised 70,361 participants with a mean age of 64.8 years. The primary outcome of interest was CKD progression, defined as a composite of kidney failure (initiation of maintenance dialysis, kidney transplantation, or sustained eGFR <15 mL/min/1.73 m2), a sustained reduction in eGFR of at least 50% from baseline, or death due to kidney failure. Secondary outcomes included the annual rate of eGFR decline (slope) and the risk of kidney failure alone. Researchers utilized inverse variance-weighted meta-analysis to pool treatment effects and assessed whether baseline eGFR or urinary albumin-to-creatinine ratio (UACR) modified the treatment response.

Results: Consistent Benefit Across the Spectrum

Primary Outcome: CKD Progression

Over the course of the trials, 2,314 participants experienced CKD progression. The meta-analysis revealed that SGLT2 inhibitors significantly reduced the risk of CKD progression compared to placebo. The event rate was 25.4 per 1000 patient-years in the SGLT2 inhibitor group versus 40.3 per 1000 patient-years in the placebo group. This translates to a hazard ratio (HR) of 0.62 (95% CI, 0.57-0.68), representing a 38% relative risk reduction.

Subgroup Analysis: eGFR and Albuminuria

One of the most critical findings of this study was the consistency of the treatment effect across all baseline eGFR categories. The HRs for CKD progression were as follows:

  • eGFR ≥60 mL/min/1.73 m2: HR 0.61 (95% CI, 0.52-0.71)
  • eGFR 45 to <60 mL/min/1.73 m2: HR 0.57 (95% CI, 0.47-0.70)
  • eGFR 30 to <45 mL/min/1.73 m2: HR 0.64 (95% CI, 0.54-0.75)
  • eGFR <30 mL/min/1.73 m2: HR 0.71 (95% CI, 0.60-0.83)

The P-value for trend was 0.16, indicating that the relative benefit does not significantly diminish as kidney function declines. Even in patients with Stage 4 CKD (eGFR <30), where the risk of adverse events is highest, SGLT2 inhibitors provided a clear and significant protective effect.

Similarly, the degree of baseline albuminuria did not modify the relative benefit of SGLT2 inhibitors (P-trend = 0.49). For patients with minimal albuminuria (UACR ≤30 mg/g), the HR was 0.58 (95% CI, 0.44-0.76). For those with microalbuminuria (30-300 mg/g), the HR was 0.74 (95% CI, 0.57-0.96), and for those with macroalbuminuria (>300 mg/g), the HR was 0.57 (95% CI, 0.52-0.64). This is a landmark finding, as it extends the evidence base to the “normoalbuminuric” population, who were previously excluded from many major kidney trials.

eGFR Slope and Kidney Failure

Beyond the composite endpoint, SGLT2 inhibitors were found to significantly reduce the risk of kidney failure alone (HR 0.66; 95% CI, 0.58-0.75). Analysis of the annual rate of eGFR decline showed that SGLT2 inhibitors slowed the loss of kidney function in all subgroups. While the absolute difference in slope was more pronounced in patients with higher levels of albuminuria (who typically have a faster rate of decline), the relative benefit remained robust in those with low albuminuria and across all eGFR tiers.

Mechanistic Insights and Clinical Implications

The consistent benefit of SGLT2 inhibitors across such diverse subgroups suggests that their renoprotective mechanisms are not solely dependent on glucose lowering or the reduction of albuminuria. While the initial “dip” in eGFR upon starting SGLT2 inhibitors reflects a reduction in intraglomerular pressure (a hemodynamic effect), long-term protection likely involves multiple pathways. These include reduced metabolic demand on proximal tubule cells, decreased tubulointerstitial inflammation, and improved oxygenation of the kidney medulla.

From a clinical perspective, these data argue for the “de-siloing” of CKD management. Rather than withholding SGLT2 inhibitors until a patient develops significant proteinuria or their eGFR drops to a specific range, the findings suggest that early and broad initiation is beneficial. Furthermore, the safety and efficacy demonstrated in patients with eGFR <30 mL/min/1.73 m2 provide reassurance for continuing or even starting therapy in late-stage CKD, provided the patient is not yet on dialysis.

Expert Commentary and Limitations

Experts in the field note that this meta-analysis effectively answers the “who to treat” question with a resounding “nearly everyone with CKD risk.” The inclusion of patients with heart failure and those without diabetes in the meta-analysis further underscores that SGLT2 inhibitors are organ-protective drugs, not just diabetes drugs. However, the study does have limitations. Most participants were already receiving RAS inhibitors, so the incremental benefit in patients not on standard-of-care therapy is less clear, though unlikely to be lower. Additionally, while the relative risk reduction is consistent, the absolute risk reduction is naturally greater in patients with higher baseline risk (higher albuminuria and lower eGFR), which may influence cost-effectiveness discussions in different healthcare systems.

Conclusion

The SMART-C meta-analysis provides the most definitive evidence to date that SGLT2 inhibitors lower the risk of CKD progression and kidney failure across the full spectrum of eGFR and albuminuria. By demonstrating efficacy in Stage 4 CKD and in patients with minimal albuminuria, this study removes the last major barriers to the routine clinical use of these agents. For clinicians, the message is clear: SGLT2 inhibitors should be considered a foundational component of therapy for patients with type 2 diabetes, heart failure, or established CKD, regardless of their specific baseline kidney metrics.

References

Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026 Jan 20;335(3):233-244. doi: 10.1001/jama.2025.20834. PMID: 41203232.

Tags:
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

No Comments
SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

Highlights

– Meta-analysis of 10 randomized placebo-controlled trials (SMART‑C; n=70,361) finds SGLT2 inhibitors lower CKD progression by ~38% (HR 0.62) and kidney failure by ~34% (HR 0.66).

– Benefits were consistent across baseline eGFR categories including eGFR <30 mL/min/1.73 m2 (stage 4 CKD) and across UACR ranges including normoalbuminuria (≤30 mg/g).

– SGLT2 inhibitors slowed the annual eGFR decline in all subgroups and showed consistent direction of effect in participants with and without diabetes.

Background and disease burden

Chronic kidney disease (CKD) affects hundreds of millions globally and is a major driver of cardiovascular morbidity, kidney failure, and healthcare costs. Historically, renin–angiotensin system (RAS) blockade has been the cornerstone of slowing CKD progression, with benefit greatest in patients with higher albuminuria. Sodium–glucose cotransporter 2 (SGLT2) inhibitors were developed as glucose-lowering agents but, over the past decade, have shown reproducible cardiorenal benefits beyond glycemic control. Early randomized trials demonstrated renal protection in selected populations; uncertainty persisted about efficacy in patients with advanced CKD (stage 4, eGFR <30 mL/min/1.73 m2) and in those with little or no albuminuria.

Study design and methods

The SGLT2 Inhibitor Meta‑Analysis Cardio‑Renal Trialists’ Consortium (SMART‑C) pooled individual-trial and trial-level data from randomized, double‑blind, placebo‑controlled SGLT2 inhibitor trials that met prespecified criteria (label indication for reducing CKD progression, ≥500 participants per arm, ≥6 months follow-up). Ten trials contributed, totaling 70,361 participants with mixed indications (type 2 diabetes, CKD, heart failure). Primary kidney outcome was CKD progression, defined as kidney failure, ≥50% decline in eGFR, or death due to kidney failure. Secondary outcomes included annual eGFR slope and kidney failure alone. Treatment effects for individual trials were combined using inverse variance–weighted meta-analysis. Subgroup analyses were prespecified for baseline estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR).

Key findings

Population: Mean age 64.8 years; 35.0% female. Across the pooled cohort there were 2,314 CKD progression events (3.3%) and 988 kidney-failure events (1.4%).

Primary kidney composite outcome (CKD progression)

SGLT2 inhibitor therapy reduced the risk of CKD progression from 40.3 to 25.4 events per 1,000 patient‑years (hazard ratio [HR] 0.62; 95% CI, 0.57–0.68). The benefit was consistent across baseline eGFR strata:

  • eGFR ≥60 mL/min/1.73 m2: HR 0.61 (95% CI, 0.52–0.71)
  • eGFR 45 to <60: HR 0.57 (95% CI, 0.47–0.70)
  • eGFR 30 to <45: HR 0.64 (95% CI, 0.54–0.75)
  • eGFR <30 (stage 4): HR 0.71 (95% CI, 0.60–0.83)

There was no statistically significant trend across eGFR categories (P for trend = .16), indicating a broadly similar relative risk reduction across the spectrum of kidney function. Although point estimates vary, confidence intervals overlap and favor treatment in all eGFR bands, including stage 4 CKD.

Effect by albuminuria (UACR)

SGLT2 inhibitors reduced CKD progression across UACR strata:

  • UACR ≤30 mg/g (normoalbuminuria): HR 0.58 (95% CI, 0.44–0.76)
  • UACR >30–300 mg/g (microalbuminuria): HR 0.74 (95% CI, 0.57–0.96)
  • UACR >300 mg/g (macroalbuminuria): HR 0.57 (95% CI, 0.52–0.64)

P for trend = .49, indicating no clear interaction between baseline albuminuria and relative benefit.

Kidney-failure outcome and eGFR slope

SGLT2 inhibitors also reduced kidney failure alone (HR 0.66; 95% CI, 0.58–0.75). Across all eGFR and UACR subgroups, treatment slowed the annual eGFR decline compared with placebo; this pattern persisted when analyses were stratified by diabetes status, demonstrating benefit in patients with and without diabetes.

Clinical and absolute benefit considerations

Relative risk reductions were clinically meaningful across the population. Absolute benefit will of course vary by baseline risk: patients with lower eGFR or higher albuminuria have higher baseline event rates and therefore larger absolute reductions in events. Importantly, even participants with low baseline albuminuria or stage 4 CKD—a group often excluded from earlier trials or considered less likely to benefit—showed reduced progression rates.

Safety, tolerability, and practical considerations

Although the SMART‑C paper focused on efficacy across kidney strata, established safety data from the SGLT2 program remain relevant. Known adverse effects include an increased risk of genital mycotic infections and, rarely, diabetic ketoacidosis (primarily in insulin-dependent or type 1 diabetes). An initial acute dip in eGFR after SGLT2 inhibitor initiation is typical and generally stabilizes to a slower long-term decline; this hemodynamic effect should not, in most cases, prompt discontinuation. Volume depletion and hypotension may occur, particularly in patients on high-dose diuretics—monitoring and temporary dose adjustments may be necessary. Importantly, glycemic efficacy declines with lower eGFR, but cardiorenal protection persists, supporting use for organ protection independent of glucose lowering.

Expert commentary and biological plausibility

These findings align with a growing mechanistic and clinical literature. Mechanisms by which SGLT2 inhibitors protect the kidney include restoration of tubuloglomerular feedback leading to reduced intraglomerular pressure; natriuresis and blood pressure lowering; improved metabolic milieu; reductions in renal inflammation, hypoxia, and fibrosis; and favorable hemodynamic and neurohormonal effects. The consistency across eGFR and UACR suggests multiple convergent mechanisms beyond simple glycemic control.

From a clinical-policy perspective, the SMART‑C meta-analysis strengthens the argument for broadening SGLT2 inhibitor use to patients at high risk of CKD progression irrespective of baseline albuminuria or stage of kidney impairment, while remaining attentive to regulatory labeling and individual safety considerations.

Limitations and generalizability

Key limitations include heterogeneity across contributing trials in enrollment criteria, background therapies, and endpoint ascertainment. Though the meta-analysis pooled large numbers, the absolute number of events in some subgroups (notably very low eGFR without albuminuria) remains limited, and trials differ in representation of non‑white populations and women. Outcomes and safety were trial-based and may not wholly reflect routine practice, where adherence and comorbidity interplay differ. Finally, regulatory labeling varies by agent and jurisdiction; clinicians must balance trial evidence with local prescribing guidance.

Clinical implications and practice recommendations

For clinicians managing patients with type 2 diabetes, CKD, or heart failure, this meta-analysis provides robust evidence that SGLT2 inhibitors reduce CKD progression and kidney failure across the full range of baseline kidney function and albuminuria. Practical steps include:

  • Consider initiating or continuing SGLT2 inhibitors in eligible patients at risk for CKD progression, even when eGFR is in the stage 4 range, after evaluating potential risks and local labeling.
  • Anticipate an early eGFR dip (usually small and transient) and monitor renal function and volume status; do not reflexively stop therapy unless the decline is clinically concerning.
  • Continue RAS blockade when tolerated—SGLT2 inhibitors are additive to RAS inhibition for renal protection.
  • Monitor for known AEs (genital infections, volume depletion, ketoacidosis in susceptible patients) and provide anticipatory counseling.

Research and policy gaps

Remaining questions include optimal initiation thresholds under different regulatory labels, long‑term safety in advanced CKD beyond trial follow-up, real-world effectiveness in underrepresented populations, and head‑to‑head comparisons among SGLT2 drugs. Implementation research to improve equitable access and uptake is important because the greatest absolute benefits accrue in high‑risk populations who often face barriers to care.

Conclusions

The SMART‑C meta‑analysis (Neuen et al., JAMA 2025) synthesizes extensive randomized trial evidence to show that SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including in stage 4 CKD and patients with minimal albuminuria. These results support broader use of SGLT2 inhibitors for kidney protection, informed by individual patient factors and regulatory guidance, and underscore the class’s transformative role in nephrology and cardiometabolic care.

Funding and clinicaltrials.gov

The SMART‑C consortium meta-analysis cites trial funding and disclosures within each included trial. Individual trials had varied industry and public support; readers should consult original trial publications for specific funding and conflict-of-interest details. ClinicalTrials.gov identifiers and detailed trial protocols are available in the original trial publications referenced below.

References

1. Neuen BL, Fletcher RA, Anker SD, et al; SGLT2 Inhibitor Meta‑Analysis Cardio‑Renal Trialists’ Consortium (SMART‑C). SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta‑Analysis. JAMA. 2025 Nov 7. doi:10.1001/jama.2025.20834. PMID: 41203232.

2. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. (CREDENCE trial)

3. Heerspink HJL, Stefánsson BV, Correa‑Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436–1446. (DAPA‑CKD)

4. Heerspink HJL, Desai M, Kitzman DW, et al. Empagliflozin and Kidney Outcomes in Patients with Chronic Kidney Disease. N Engl J Med. 2023; (EMPA‑KIDNEY).

5. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: systematic review and meta‑analysis. Lancet. 2019;393(10166):31–39.

6. KDIGO. Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022. (Guideline statements on kidney protection evolve as new evidence emerges.)

Note: Readers should consult individual trial reports for detailed inclusion criteria, safety analyses, and trial-specific clinical recommendations.

Tags:

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply